Introduction {#s1}
============

Skeletal muscle consists of multinuclear cells named myofibers and exhibits the ability to regenerate. When myofibers are damaged, mitotically quiescent mononuclear cells known as muscle satellite (stem) cells (MuSCs) exit quiescence and become activated and immediately start expressing MyoD (a myogenic determination gene), followed by entry into the cell cycle to yield daughter cells (myoblasts) ([@bib40]). To generate multinuclear cells, the proliferated myoblasts fuse with each other or with existing myofibers through the action of the fusion proteins 'myomaker' and 'myomixer/myomerger/minion' ([@bib3]; [@bib34]; [@bib39]; [@bib56]). The indispensable role and behaviors of MuSCs in muscle regeneration have been comprehensively investigated, leading to the establishment of an MuSC-differentiation model ([@bib29]; [@bib42]; [@bib49]).

Another ability possessed by skeletal muscle is the capacity to adapt its size in response to new milieus. A loss of muscle mass (i.e., muscle atrophy) occurs in bedridden people, patients with cancer cachexia or sepsis, or during aging, whereas an increase in muscle mass (i.e., muscle hypertrophy) is induced by resistance training. Although MuSC requirement for myofiber hypertrophy has been debated, MuSCs are required for long-term muscle hypertrophy ([@bib11]; [@bib14]; [@bib17]; [@bib18]). Furthermore, MuSCs are indispensable for supplying new nuclei to myofibers during overload-induced muscle hypertrophy ([@bib11]; [@bib18]; [@bib33]; [@bib43]). Similar to the regeneration process, myomaker is necessary for MuSC fusion with myofibers during muscle hypertrophy. [@bib18] showed that the addition of new myonuclei derived from MuSCs was severely hampered in overloaded muscle from myomaker-deficient mice. Before this cell fusion, MuSCs must escape from their quiescent state, become activated, and proliferate; however, compared with MuSC behavior during muscle regeneration, MuSC-activation/proliferation mechanisms during hypertrophy remain poorly investigated. One reason for this is that damage to skeletal muscle arises from resistance training ([@bib7]; [@bib10]; [@bib26]); therefore, previous studies have not considered whether hypertrophic muscle requires special mechanisms for MuSC activation/proliferation.

Specific forms of exercise (e.g., eccentric contraction) can result in disruption of the myofibrillar structure and leakiness of the myofiber membrane (sarcolemma) ([@bib13]; [@bib19]). However, these disruptions depend on the intensity, duration, and frequency of the administered exercise and do not unfailingly lead to lethal/substantial injury to the myofiber ([@bib19]). Intriguingly, studies conducted by Darr and Schultz suggested that MuSCs became activated and replicated, even on myofibers not overtly necrotic in eccentrically exercised soleus and extensor digitorum longus muscles of rats. This finding suggests that the existence of lethal damage to myofibers is not necessary for MuSC activation and proliferation in overloaded muscle. Given that this mechanism underlying MuSC activation/proliferation in overloaded muscle differs from that in regenerating muscle, elucidation of MuSC behaviors in overloaded muscle could facilitate the development of new therapeutic strategies for the muscle wasting or atrophy that occurs in the absence of muscle damage (as in chronic diseases and aging).

Under steady state conditions, MuSCs are maintained in an undifferentiated and quiescent state in their niche ([@bib17]), with the molecules and pathways that maintain MuSCs in the dormant state having been recently revealed ([@bib2]; [@bib6]). Among the pathways involved, the canonical Notch signaling pathway is crucial for sustaining the undifferentiated state in MuSCs. Notch signaling is an evolutionarily conserved intercellular signaling system required for cell-fate decisions and patterning events ([@bib28]). The most widely recognized primary targets of canonical Notch signaling are the (hairy and enhancer of split) *Hes* and (Hes-related; also known as Hesr/Herp/Hrt/Gridlock/Chf) *Hey* families of bHLH transcriptional-repressor genes ([@bib22]), which function to suppress MyoD and myogenin expression in MuSCs. Recently, Lahmann et al. indicated that Hes1 controls oscillatory *Myod* expression in activated/proliferating MuSCs ([@bib27]). We previously reported that neither *Hey1* (Hey1-KO) nor *Heyl* single-knockout (HeyL-KO) mice show abnormalities in regenerative ability, MyoD and myogenin expression, or MuSC number; however, double-KO mice exhibit severe regenerative defects due to a reduction in MuSC number resulting from increased MyoD and myogenin expression in the MuSCs ([@bib16]; [@bib36]). When MuSCs respond to muscle injury, *Hey1* and *Heyl* expression levels are drastically decreased; therefore, activation/proliferation of MuSCs in injured muscle do not require *Hey1* and *Heyl* expression. However, *Hey1* and *Heyl* expression and function in proliferating MuSCs in hypertrophic muscle remain unknown.

To investigate the mechanism of MuSC activation/proliferation during muscle hypertrophy, we first examined the protein-expression patterns of MyoD and Ki67 in MuSCs in overloaded muscle. During MuSC activation in acute injury or in vitro culture, almost all MuSCs initially express MyoD at the protein level and then express Ki67 ([@bib37]). However, we found that in overloaded muscle, the majority of MuSCs proliferated in the absence of MyoD protein expression. Notably, gene-expression analyses indicated that *Hey1* expression in proliferating MuSCs was decreased to the same extent as that observed in the injury model, whereas *Heyl* expression was sustained in overloaded MuSCs, suggesting that the requirement of HeyL in MuSCs differed between regenerating and overloaded muscle. Accordingly, HeyL-KO mice showed no marked defects in a muscle-injury model but exhibited decreases in the number of proliferating MuSCs, MyoD-negative cells, and incorporated myonuclei in overloaded muscle, indicating that sustained HeyL expression is critical for MuSC expansion in overloaded muscle. Finally, both muscle weight and myofiber size were attenuated in the overloaded muscle of HeyL-KO mice at 9 weeks after synergist ablation. Collectively, our findings indicate that sustained HeyL expression is necessary for effective proliferation of MuSCs in overloaded muscle, and that the MuSC-proliferation mechanism in overloaded muscle differs from that in injured muscle.

Results {#s2}
=======

Proliferation of MuSCs during muscle hypertrophy {#s2-1}
------------------------------------------------

To elucidate the molecular mechanisms by which MuSCs become activated and proliferate in overloaded muscle, the Achilles tendon in mice was cut to induce compensatory hypertrophy in plantaris muscle (tenotomy). This model relies on the compensatory adaptation of the plantaris muscle following cutting of the functionally synergistic muscles of the Achilles tendon (i.e., the gastrocnemius and soleus muscles). Surgical ablation of gastrocnemius and soleus muscles \[synergist ablation; SA\] leads to more marked increase in muscle weight than after tenotomy alone; however, the incidence of muscle damage is also increased. The rate of increase in muscle weight in the tenotomy model was lower than that in the SA model ([Figure 1A](#fig1){ref-type="fig"}), although muscle weight increased significantly ([Figure 1B](#fig1){ref-type="fig"}). Moreover, areas of muscle damage were rarely detected ([Figure 1C](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Notably, even under conditions of diminished muscle damage, we observed an increased number of Pax7^+^ cells ([Figure 1D](#fig1){ref-type="fig"}). Accordingly, we frequently observed cells positive for Ki67 (a proliferation marker) among Pax7^+^ cells ([Figure 1E](#fig1){ref-type="fig"}), and importantly, at 4 days after tenotomy, the percentage of Pax7^+^Ki67^+^ cells among Pax7^+^ cells (\~70%) was higher than that of Pax7^+^MyoD^+^ cells (\~35%), suggesting that at least \>50% of these MuSCs proliferated in the absence of MyoD expression ([Figure 1E,F](#fig1){ref-type="fig"}).

![Tenotomy induces activation and proliferation of muscle stem cells in the absence of substantial muscle damage.\
(**A**) Two mouse models that induce muscle hypertrophy. (**B**) Plantaris muscle weight relative to body weight (mg/g) after tenotomy (gray circle) or the weight of contralateral sham-operated muscle (open circle). \*\*p\<0.01. (**C**) H and E staining of plantaris muscle sections at 4 days after tenotomy. Scale bar: 500 µm. Right three images in squares represent magnifications of the left image. (**D**) Relative number of MuSCs in plantaris muscle sections after tenotomy (gray circle) or in contralateral sham muscle sections (open circle). \*\*p\<0.01. (**E**) Percentage of Ki67^+^ cells among Pax7^+^ cells in contralateral sham (open circle) or tenotomy induced plantaris muscle (gray circle). \*\*p\<0.01. (**F**) Percentage of MyoD^+^ cells among Pax7^+^ cells in contralateral sham (open circle) or tenotomy induced plantaris muscle (gray circle). \*\*p\<0.01. Data represent the means ± standard deviation. A two-sided Student's *t* test or Welch's *t* test was performed.\
10.7554/eLife.48284.004Figure 1---source data 1.Numerical data for making the graphs in [Figure 1](#fig1){ref-type="fig"}.Experiment number corresponds to all results.](elife-48284-fig1){#fig1}

To further examine the expression pattern of MyoD and Ki67 in Pax7^+^ cells in overloaded muscle, we isolated single myofibers from overloaded plantaris muscle and immunostained them concurrently for MyoD and Ki67 ([Figure 2A](#fig2){ref-type="fig"}) and used 3 day cultured single myofibers isolated from intact skeletal muscle as a positive control ([Figure 2A](#fig2){ref-type="fig"}). MyoD and Ki67 were expressed by almost all Pax7^+^ cells on the cultured myofibers ([Figure 2B](#fig2){ref-type="fig"}), with these results similar to those reported previously using an in vitro culture model and in vivo regenerating muscle ([@bib37]; [@bib54]). By contrast, the majority (\~70%) of activated Pax7^+^ cells on overloaded myofibers were positive for Ki67 but negative for MyoD ([Figure 2B,C](#fig2){ref-type="fig"}), which agreed with our immunohistochemical analysis ([Figure 1E,F](#fig1){ref-type="fig"}). In sham-operated muscle, 93% of Pax7^+^ cells on myofibers expressed neither MyoD nor Ki67, indicating that these cells were in a quiescent state ([Figure 2B,C](#fig2){ref-type="fig"}).

![Majority of muscle stem cells proliferate on undamaged overloaded myofibers in the absence of MyoD expression.\
(**A**) Experimental scheme for analyzing the number and properties of MuSCs on isolated single myofibers. At 4 days after tenotomy, single myofibers were isolated and immediately fixed. Single myofibers cultured for 3 days were used as positive controls for immunostaining. (**B**) Immunostaining of Pax7 (red), MyoD (green), and Ki67 (white) in MuSCs on 3 day cultured myofibers (Culture 3d; positive control), freshly isolated myofibers of sham muscle (Sham), or freshly isolated myofibers at 4 days after tenotomy (Tenotomy). Nuclei were counterstained with DAPI. Scale bar: 50 μm. (**C**) Bar graph showing frequencies of MyoD^+^Ki67^+^ (blue column), MyoD^−^Ki67^−^ (red column), MyoD^+^Ki67^−^ (green column), and MyoD^−^Ki67^+^ (purple column) cells on 3 day cultured myofibers, sham myofibers, or myofibers at 4 days after tenotomy. The number associated with the majority phenotype in Pax7^+^ cells is indicated in the numerator of each bar. Total number of Pax7^+^ cells is indicated in the denominator of each bar. (**D**) Histogram showing the frequency of the listed number of MuSCs per myofiber in the case of sham myofibers (white bar, *n* = 46) or myofibers at 4 days after tenotomy (blue bar, *n* = 49). The X-axis indicates the number of MuSCs per myofiber, and the Y-axis shows the frequency of myofibers harboring the indicated number of MuSCs. (**E, F**) Frequency of MyoD^−^Ki67^−^ (**E**) or MyoD^−^Ki67^+^ (**F**) MuSCs on single myofibers: sham control (white bar, *n* = 41) versus 4 days after tenotomy (blue bar, *n* = 49). The X-axis indicates the percentage of MyoD^−^Ki67^−^ or MyoD^−^Ki67^+^ MuSCs per myofiber. The Y-axis shows the frequency of myofibers with the indicated percentage of MyoD^−^Ki67^−^ (**E**) or MyoD^−^Ki67^+^ (**F**) MuSCs per myofiber.\
10.7554/eLife.48284.006Figure 2---source data 1.Numerical data for making the graphs in [Figure 2](#fig2){ref-type="fig"}.Experiment number corresponds to all results ([Figure 2C](#fig2){ref-type="fig"}). Data in [Figure 2-D-F](#fig2){ref-type="fig"} marked by gray color are used for analyses in [Figure 2-D-F](#fig2){ref-type="fig"} marked by yellow color.](elife-48284-fig2){#fig2}

Our results showed that few areas of muscle damage were present in our overload model ([Figure 1C](#fig1){ref-type="fig"}); however, factors released from locally damaged myofibers could have affected MuSC activation/proliferation in the overloaded muscle. In this scenario, MuSCs would proliferate in a restricted area and on a few myofibers. Conversely, if MuSCs respond to other stimuli (e.g., mechanical stimulation), MuSCs on almost all myofibers would escape from the quiescent state and proliferate on undamaged myofibers. To investigate this, we determined both the number and properties of Pax7^+^ cells on single myofibers by using isolated single myofibers in the assays. Because damaged myofibers could be lost during the preparation of single myofibers due to their hyper-contraction, the observed Pax7^+^ cells were considered to be present on undamaged myofibers. Under this experimental condition, the number of Pax7^+^ cells per myofiber was increased overall in the overloaded muscles but not in only limited areas of the myofibers ([Figure 2D](#fig2){ref-type="fig"}). We then examined the properties of Pax7^+^ cells on single myofibers. In this analysis, if all five Pax7^+^ cells present on a myofiber were found to be in the quiescent state (MyoD^−^Ki67^−^), they were categorized into 100% in [Figure 2E](#fig2){ref-type="fig"} and 0% in [Figure 2F](#fig2){ref-type="fig"}, respectively. However, if zero to one of the five Pax7^+^ cells on the myofiber were in the quiescent state, the cells were categorized into the 0% to 20% range in [Figure 2E](#fig2){ref-type="fig"}, whereas if three to four of the five Pax7^+^ cells were MyoD^−^Ki67^+^, they were categorized into the 60% to 80% range in [Figure 2F](#fig2){ref-type="fig"}. As expected, almost all sham-operated myofibers harbored only quiescent MuSCs (MyoD^−^Ki67^−^). By contrast,\>80% of overloaded myofibers harbored \<40% quiescent MuSCs ([Figure 2E](#fig2){ref-type="fig"}), and \~60% of the myofibers harbored \>40% MyoD^−^Ki67^+^ cells ([Figure 2F](#fig2){ref-type="fig"}). These results suggested that escape of MuSCs from quiescent state did not occur in a restricted area of the overloaded myofibers, and that almost all myofibers responded to the overload. Collectively, these data suggest that MuSCs proliferate during hypertrophy in a manner distinct from that during muscle injury.

*Heyl* expression is sustained in proliferating MuSCs in overloaded muscle {#s2-2}
--------------------------------------------------------------------------

In contrast to what occurs during the regenerative process, myofibers are retained in overloaded muscle. Accordingly, we observed proliferating MuSCs between myofibers and the basal lamina in overloaded myofibers ([Figure 3A,B](#fig3){ref-type="fig"}). Canonical Notch signaling is a critical pathway for suppressing MyoD expression in MuSCs ([@bib4]; [@bib35]), and myofibers are considered a source of Notch ligand. Therefore, we hypothesized that canonical Notch signaling is responsible for MyoD suppression in proliferating MuSCs in overloaded muscle. *Hey1*, *Heyl,* and *Hes1* are crucial primary targets of canonical Notch signaling in MuSCs ([@bib16]; [@bib27]) and function to suppress myogenic differentiation as Hey--Hes1 heterodimer complexes ([@bib36]). Moreover, *Hey1* and *Heyl* are both expressed in quiescent MuSCs, although their expression is drastically reduced during injury induced MuSC activation ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) ([@bib16]; [@bib35]). Although neither *Hey1* (Hey1-KO) nor *Heyl* single-KO (HeyL-KO) mice show impaired muscle regeneration, *Hey1/Heyl* double-KO mice exhibit increased MyoD expression in MuSCs, indicating redundant roles of Hey1 and HeyL in MuSCs ([@bib16]; [@bib36]). To determine the expression of Notch target genes, we performed RNA-seq analyses and found that their expression was overall sustained in overloaded MuSCs at 4 days after tenotomy ([Figure 3C](#fig3){ref-type="fig"}). Specifically, we observed significant sustained expression of *Heyl* in overloaded MuSCs as compared with that observed in regenerating MuSCs ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We then confirmed the RNA-seq results by quantitative reverse transcription polymerase chain reaction (qRT-PCR), with the data showing that *Heyl* but not *Hey1* expression was sustained in tenotomy induced MuSCs ([Figure 3D](#fig3){ref-type="fig"}). Additionally, we measured levels of *Col5a1*, *Col5a3*, and *Col6a1* expression as newly identified direct target genes of Rbp-J (the major transcriptional effector of Notch signaling) in MuSCs ([@bib2]). We found that their expression levels were reduced at 2 days after surgery but comparable to levels in quiescent MuSCs at 4 days after surgery, when MuSCs exhibit active proliferation in overloaded muscle ([Figure 3E](#fig3){ref-type="fig"}). Moreover, RNA-seq data indicated increased expression levels of cell cycle-related genes and sustained expression of *Myf5* in overloaded MuSCs ([Figure 3B](#fig3){ref-type="fig"}). These findings suggested that MuSCs proliferate under activation of canonical Notch signaling in the overload mouse model, and that sustained *Heyl* expression is a feature of proliferating MuSCs in overloaded muscle.

![Relative mRNA expression of Notch target genes in muscle stem cells in regenerating versus overloaded muscle.\
(**A**) Immunostaining of laminin α2 (LNα2; red) and YFP (green) in isolated myofibers derived from *Pax7^CreERT2+^::Rosa^YFP^* (Rosa-YFP) mice at 4 days after tenotomy. Nuclei were counterstained with DAPI. Scale bar: 10 µm. (**B**) Immunostaining of Pax7 (red), laminin α2 (LNα2; green), and EdU (white) in sections from *C57BL/6* mice at 4 days after tenotomy. Nuclei were counterstained with DAPI. Arrow or arrowhead indicate EdU^+^ or EdU^−^ Pax7^+^ cells. Scale bar: 20 µm. (**C**) RNA-seq analyses of Notch, myogenic, and cell-proliferation-related genes in MuSCs from sham or overloaded plantaris muscle of Rosa-YFP at 4 days after tenotomy. (**D, E**) Mononuclear myogenic cells were isolated from intact muscle (Cont; red), damaged muscle at 2 days after cardiotoxin injection (CTX 2d), sham-operated muscle (Cont; blue), or overloaded plantaris muscle of C57BL/6. Relative expression of *Hey1* and *Heyl* (**D**) and three other canonical Notch target genes (*Col5a1*, *Col5a3*, and *Col6a1*) were compared between Cont and CTX/tenotomy samples (**E**).](elife-48284-fig3){#fig3}

Proliferation ability of MuSCs in HeyL-KO mice {#s2-3}
----------------------------------------------

We then investigated the role of sustained *Heyl* expression in MuSC behavior in overloaded muscle by inducing tenotomy in HeyL-KO mice and comparing the effects with those in Hey1-KO and control mice ([Figure 4A](#fig4){ref-type="fig"}). Interestingly, in HeyL-KO mice, the frequency of Ki67^+^MyoD^+^ and Ki67^+^MyoD^−^ cells among Pax7^+^ cells increased and decreased, respectively, at 4 days after surgery ([Figure 4B,C](#fig4){ref-type="fig"}); therefore, the ratio of MyoD^+^ to MyoD^−^ cells among proliferating cells (Ki67^+^Pax7^+^) was markedly higher in HeyL-KO mice than in control and Hey1-KO mice ([Figure 4D](#fig4){ref-type="fig"}). Moreover, the frequency of Ki67^+^ cells in HeyL-KO mice was similar to that in control mice, whereas the total number of Pax7^+^ cells per myofiber at 4 days after surgery was significantly lower in HeyL-KO mice than in control and Hey1-KO mice ([Figure 4E](#fig4){ref-type="fig"}), suggesting that the loss of *Heyl* affected MuSC proliferation but not their activation. The results at 7 days after surgery were similar to those at 4 days after surgery ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). By contrast, in vivo regeneration and in vitro culture assays revealed no notable differences between control and HeyL-KO mice ([Figure 4---figure supplements 2](#fig4s2){ref-type="fig"} and [3](#fig4s3){ref-type="fig"}). Collectively, these results indicate that the sustained expression of *Heyl* in MuSCs is critical for suppressing MyoD expression in overloaded muscles, and that the loss of *Heyl* impairs the proliferation of MuSCs by biasing them toward differentiation (MyoD expression).

![Increased ratio of MyoD-expressing myogenic cells and decreased cell number in overloaded HeyL-KO mice.\
(**A**) Experimental scheme for analyzing Pax7^+^ cells on plantaris myofibers derived from control (Cont), Hey1-KO (1KO), or HeyL-KO (LKO) mice at 4 days after tenotomy (Ope). (**B**) Immunostaining of Pax7 (red), MyoD (green), and Ki67 (white) in MuSCs on freshly isolated myofibers at 4 days after tenotomy from Cont, 1KO, or LKO mice. Nuclei were counterstained with DAPI. Scale bar: 20 μm. (**C**) Frequency of MyoD^−^Ki67^+^ (left) or MyoD^+^Ki67^+^ (right) cells among Pax7^+^ cells on myofibers: sham (open circle) versus 4 days after tenotomy (closed circle), derived from Cont (light gray, *n* = 5), 1KO (black, *n* = 4), or LKO (blue, *n* = 5) mice. \*\*p\<0.01. N.S.: not significant. (**D**) Ratio of MyoD^+^ to MyoD^−^ cells among Ki67^+^Pax7^+^ cells on myofibers at 4 days after tenotomy, derived from Cont (light gray, *n* = 5), 1KO (black, *n* = 4), or LKO (blue, *n* = 5) mice. \*\*p\<0.01. N.S.: not significant. (**E**) Number of Pax7^+^ cells on myofibers: sham (open circle) versus 4 days after tenotomy (closed circle), derived from Cont (light gray, *n* = 5), 1KO (black, *n* = 4), or LKO (blue, *n* = 5) mice. \*\*p\<0.01. N.S.: not significant. Data represent the mean ± standard deviation. One-way ANOVA, followed by the Tukey--Kramer test, was used for statistical analyses.\
10.7554/eLife.48284.016Figure 4---source data 1.Numerical data for making the graphs in [Figure 4](#fig4){ref-type="fig"}.Experiment number corresponds to all results.](elife-48284-fig4){#fig4}

The supply of new myonuclei is diminished in overloaded muscle in HeyL-KO mice {#s2-4}
------------------------------------------------------------------------------

We then compared the numbers of new myonuclei supplied by MuSCs in overloaded muscle from control, Hey1-, and HeyL-KO mice. Proliferating MuSCs were labeled with EdU ([Figure 5A](#fig5){ref-type="fig"}), and MuSC-derived nuclei (EdU^+^ myonuclei) were discriminated from other nuclei after staining for dystrophin \[i.e., we detected new MuSC-derived myonuclei as EdU^+^ nuclei located beneath the myofiber membrane (marked by dystrophin staining)\] ([@bib16]) ([Figure 5B](#fig5){ref-type="fig"}). Approximately 20 or 60 myonuclei were labeled per cross-section from control/Hey1-KO mice at 4 or 7 days after surgery, respectively ([Figure 5C](#fig5){ref-type="fig"}), which suggested that the proliferating MuSCs actively fused with myofibers during this period. Notably, in HeyL-KO mice, we detected \<50% as many new (EdU^+^) myonuclei per one cross-section or per 100 myofibers as compared with that detected in control and Hey1-KO mice at 7 days after surgery ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Additionally, the number of myonuclei per 100 myofibers in HeyL-KO mice after tenotomy was lower than that in control mice ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Furthermore, in sham-operated muscle, EdU^+^ myonuclei were rarely detected in control, Hey1-, and HeyL-KO mice ([Figure 5C](#fig5){ref-type="fig"}), which indicated that changes in the number of EdU^+^ myonuclei were due to MuSC fusion with myofibers in response to overload. However, similar to a previous MuSC-depletion study ([@bib33]), the decrease in the number of new myonuclei in HeyL-KO mice did not correlate with muscle weight at this time point ([Figure 5D](#fig5){ref-type="fig"}). These findings indicate that the impaired expansion of MuSCs (due to increased MyoD expression) resulted in decreased new myonuclei in the overloaded muscle of HeyL-KO mice.

![Decreased number of new myonuclei supplied by muscle stem cells in overloaded HeyL-KO muscle.\
(**A**) Experimental scheme for analyzing new MuSC-derived myonuclei in plantaris muscle of control (Cont), Hey1-KO (1KO), or HeyL-KO (LKO) mice at 4 or 7 days after tenotomy. Arrowheads indicate the day of EdU injection. (**B**) Arrows indicate new myonuclei supplied by MuSCs in overloaded muscle of Cont, 1KO, or LKO mice. MuSC-derived myonuclei were labeled with EdU (white) and located inside the staining for dystrophin (Dys; green). Nuclei were counterstained with DAPI. Scale bar: 50 μm. (**C**) Number of EdU^+^ myonuclei in muscle: sham (open circle) versus tenotomy (closed circle). Left graph: results at 4 days after tenotomy (Ope-4d) (Cont: light gray, *n* = 4; LKO: blue, *n* = 4). Right graph: results at 7 days after tenotomy (Cont: light gray, *n* = 8; 1KO: black, *n* = 6; LKO: blue, *n* = 7). \*\*p\<0.01. N.S.: not significant. (**D**) Ratio of overloaded muscle weight to sham muscle weight in Cont (light gray, *n* = 8), 1KO (black, *n* = 6), or LKO (blue, *n* = 8) mice at 7 days after tenotomy. N.S.: not significant. Data represent the mean ± standard deviation. One-way ANOVA, followed by the Tukey--Kramer or Bonferroni test, was used for statistical analyses.\
10.7554/eLife.48284.020Figure 5---source data 1.Numerical data for making the graphs in [Figure 5](#fig5){ref-type="fig"}.Experiment number corresponds to all results.](elife-48284-fig5){#fig5}

HeyL loss affects muscle weight and myofiber size in SA-induced hypertrophy {#s2-5}
---------------------------------------------------------------------------

In contrast to tenotomy, a previous study reported that SA allows the plantaris muscle to continue increasing in size, and that the effects of diminished MuSC number and function were observed at a later stage of SA-induced hypertrophy ([@bib14]). To examine whether the decreased number of new myonuclei derived from MuSCs in HeyL-KO mice affects muscle weight and myofiber size, we induced SA in control and HeyL-KO mice ([Figure 6A](#fig6){ref-type="fig"}). Similar to the previous study, the muscle weight to body weight ratio increased by up to 190% relative to that in sham contralateral muscle in control mice (sham vs. SA: 0.65 ± 0.04 vs. 1.26 ± 0.20 mg/g) ([Figure 6B](#fig6){ref-type="fig"}) ([@bib14]). Moreover, histologic analyses of plantaris muscle revealed an increased myofiber cross-sectional area in control mice (sham vs. SA: 1127 ± 227 vs. 1794 ± 349 μm^2^) ([Figure 6C,D](#fig6){ref-type="fig"}); however, in HeyL-KO mice, the growth rate of plantaris muscle was lower than that in control mice (HeyL-KO sham vs. SA: 0.63 ± 0.05 vs. 1.07 ± 0.13 mg/g) ([Figure 6B](#fig6){ref-type="fig"}), and after SA, myofibers in the KO mice were also smaller than those in control mice (sham vs. SA: 1116 ± 126 vs. 1443 ± 205 μm^2^) ([Figure 6C,D](#fig6){ref-type="fig"}). Furthermore, HeyL-KO mice following SA tended to have fewer myonuclei compared with control mice ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These findings indicate that the loss of *Heyl* in MuSCs results in blunted muscle hypertrophy at the late stage in SA-treated mice.

![Blunted hypertrophy in HeyL-KO mice at 9 weeks after synergist ablation (SA).\
(**A**) Experimental scheme for analyzing the influence of HeyL-KO (LKO) on overloaded plantaris muscle at 9 weeks after SA. (**B**) Normalized plantaris muscle weight \[muscle weight/body weight (BW)\] from sham (open circle) or SA (closed circle) muscle derived from Cont (light gray, *n* = 4) or LKO mice (blue, *n* = 10). \*p\<0.05. N.S.: not significant. (**C**) Immunostaining of laminin α2 (green) in sham or SA plantaris muscle derived from Cont or LKO mice. Scale bar: 50 μm. (**D**) Average myofiber cross-sectional area (CSA) values from sham (open circle) or SA (closed circle) plantaris muscle derived from Cont (light gray, *n* = 4) or LKO mice (blue, *n* = 10). \*p\<0.05. N.S.: not significant. Data represent the mean ± standard deviation. One-way ANOVA, followed by the Tukey--Kramer test, was used for statistical analyses.\
10.7554/eLife.48284.024Figure 6---source data 1.Numerical data for making the graphs in [Figure 6](#fig6){ref-type="fig"}.Experiment number corresponds to all results.](elife-48284-fig6){#fig6}

Discussion {#s3}
==========

One of the most crucial findings obtained in this study was that MuSCs proliferated in the absence of MyoD expression by expressing HeyL in overloaded muscle ([Figure 7A](#fig7){ref-type="fig"}), unlike findings in well-known myogenic differentiation models. Therefore, the mechanism of MuSC proliferation in overloaded muscle differs from those described in regenerating muscle and in vitro culture systems, which have provided the basis for concepts of MuSC proliferation and differentiation ([@bib17]; [@bib54]; [@bib55]). Here, we showed that in overloaded muscle, MuSCs proliferated between the basal lamina and myofibers. By contrast, in regenerating muscle, MuSCs proliferate beneath the retained basal lamina ('ghost fibers'), where damaged myofibers have been removed by macrophages ([@bib50]). Single-myofiber culture does not allow MuSCs to proliferate beneath the basal lamina, because MuSCs escape from the niche and proliferate outside the basal lamina ([@bib46]; [@bib53]). The environment in which MuSCs proliferate is considered to be responsible for the difference in MyoD- and HeyL-expression patterns in MuSCs between regenerating and overloaded muscle.

![Model of MuSC behavior in overloaded muscle.\
(**A**) Distinct environments for MuSC proliferation between regenerating and overloaded muscle. (**B**) Essential roles of HeyL in MuSC proliferation in overloaded muscle.](elife-48284-fig7){#fig7}

Based on our results, the kinetics of MuSC behavior in overloaded muscle also differ from those in regenerating muscles ([Figure 7A](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). In cardiotoxin (CTX)-induced regenerating muscle, MuSC activation (MyoD expression) occurs quickly, and at least 50% of MuSCs are Ki67^+^ at 1 day after injury ([@bib37]). At 2 to 3 days after injury, MuSCs proliferate vigorously and begin to express myogenin to promote MuSC fusion. In overloaded muscle, MuSC activation (Ki67 expression) is initiated 2 days after tenotomy, followed by MuSC proliferation ([Figure 1](#fig1){ref-type="fig"}; [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Importantly, proliferating and differentiating MuSCs co-exist for long periods, resulting in gradually increasing numbers of MuSC-derived myonuclei until 14 days after tenotomy ([Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). RNA-seq data supported this model based on elevated expression of both cell cycle-related genes and *myogenin* in overloaded MuSCs.

*Hey1* and *Heyl* are effector genes of canonical Notch signaling in MuSCs. In muscle-injury experiments, Hey1-KO and HeyL-KO mice showed normal muscle-regeneration ability ([@bib16]); however, in overloaded muscle, HeyL-KO mice exhibited impaired cell proliferation, which resulted in a decreased number of new myonuclei during muscle hypertrophy ([Figure 7B](#fig7){ref-type="fig"}). These results strongly support the notion that the MuSC-proliferation mechanism in the overload model differs from that in the injury model. This study did not yield direct evidence indicating active Notch signaling in MuSCs in overloaded muscle, because real-time imaging of Notch signaling is challenging. However, the following results suggested that Notch signaling was activated in proliferating MuSCs of overloaded muscle at 4 days after tenotomy (when MuSCs proliferate actively): 1) in addition to *Heyl*, proliferating MuSCs expressed Notch-related genes and *Col5a1*, *Col5a3*, and *Col6a1*, which are direct target genes associated with canonical Notch signaling ([@bib2]); and 2) MuSCs proliferated on myofibers, which are presumed to express Notch ligands. If active Notch signaling is responsible for the sustained expression of *Heyl* via Rbp-J, a key question that remains unanswered is how MuSCs suppress *Hey1* expression. Although RNA-seq data strongly suggested active Notch signaling in the overloaded MuSCs, we cannot exclude the possibility that Notch signaling is inactive in proliferating MuSCs, and that a Notch-independent mechanism induces *Heyl* expression. To the best of our knowledge, this is the first evidence indicating that expression of Notch effector genes is differentially regulated in MuSCs. Elucidation of the detailed mechanisms by which *Hey1* and *Heyl* expression are regulated will promote an in-depth understanding of the mechanism of MuSC proliferation during muscle hypertrophy.

Exercise-induced muscle damage are reportedly involved in skeletal muscle hypertrophy ([@bib9]; [@bib44]). Because MuSCs are indispensable for repairing damaged myofibers ([@bib29]; [@bib40]; [@bib42]), MuSCs are likely involved in cases of exercise that produces substantial damage to myofibers. Our experimental methods involved tenotomy, which causes less damage than SA. Additionally, we used isolated single myofibers in order to allow examination of MuSCs on undamaged myofibers. We found that almost all overloaded myofibers harbored proliferating MuSCs rather than quiescent MuSCs, suggesting that even if local injury had occurred, the locally injured areas were not responsible for the MuSC activation and proliferation observed here. Collectively, our results demonstrated that MuSCs could become activated and proliferate and ultimately supply new nuclei, even in environments producing minimal myofiber damage, indicating that substantial damage is unnecessary for MuSC activation/proliferation in hypertrophic muscles.

Our results showed that in overloaded muscle, fewer proliferating MuSCs were present in HeyL-KO mice than in control mice, because the MuSCs were directed toward differentiation; however, the percentage of total Ki67^+^ cells among MuSCs in HeyL-KO mice was similar to that in control mice, which suggests that MuSC activation was unaffected by the absence of *Heyl*. This result suggested that MuSCs require activation/proliferation-inducing factors; however, the mechanisms underlying MuSC activation from the quiescent state in overloaded muscle remain unclear. Muscle-derived nitric oxide-stimulated secretion of hepatocyte growth factor (HGF) from the extracellular matrix is a potential pathway for MuSC activation/proliferation in overloaded muscle ([@bib1]; [@bib48]; [@bib52]). Using mice in which the HGF receptor (c-Met) was specifically deleted in MuSCs, [@bib51] showed that HGF-specific signaling did not affect MuSC activation/proliferation in an injury model. However, compared with the hypertrophy model, the injury model could potentially involve several complementary factors that contribute to MuSC activation/proliferation; consequently, the contribution of HGF might be obscured in the injury model. Therefore, MuSC-specific c-Met-deleted mice could potentially exhibit defects in MuSC activation and proliferation in overloaded muscle.

Even in overloaded muscle, inflammation is a candidate pathway for inducing MuSC activation and proliferation. [@bib32] reported that treatment with non-steroidal anti-inflammatory drugs (inhibitors of synthesis of prostaglandins, including PGE2) suppressed MuSC activity in overloaded human muscle. Furthermore, [@bib21] showed that PGE2 promotes MuSC proliferation in an injury mouse model. In the present study, we observed no marked increase in macrophage number at 2 days after tenotomy, when some MuSCs were already activated, which suggests that macrophage infiltration is no required for MuSC activation in overloaded muscle. At 4 days after tenotomy, macrophage number was only slightly increased (data not shown), although their number at this stage is already extremely high in an injury model. Macrophage-depletion models could help ascertain whether MuSCs require inflammation for their proliferation in an undamaged overloaded muscle.

Additionally, a mechanical stimulus could provide insight into a possible pathway for MuSC activation/proliferation in overloaded muscle. In developing myofibers, mechanical-stimulus-dependent Yap1 activation induces the expression of a Notch1 ligand, Jag2, which maintains the pool of myogenic progenitors ([@bib12]). Whether Yap1 is activated in MuSCs in response to mechanical stimuli remains unclear; however, the possibility exists that mechanical overload directly promotes the transition of MuSCs from the quiescent state and induces their proliferation. Investigation of these possibilities in future studies will support acquisition of a comprehensive understanding of the behaviors of MuSCs in overloaded muscle in which non-lethal damage to myofibers has occurred.

Because the ratio of myofiber nuclear content to myofiber mass remains constant during hypertrophy (known as the myonuclear domain theory), addition of new myonuclei derived from MuSCs is considered essential for increasing muscle mass ([@bib5]). However, using a MuSC-depleted model, [@bib33] showed that MuSCs play dispensable roles in muscle hypertrophy at an early stage of the hypertrophy. However, [@bib11] argued against this finding by presenting results demonstrating that plantaris muscle fails to undergo overload-induced hypertrophy in the absence of MuSCs; [@bib23] reported that neuronal nitric oxide synthase was rapidly activated (within 3 min) by overload induced using tenotomy, and that this stimulation eventually triggered the activation of mammalian target of rapamycin signaling, which is a recognized protein-synthesis pathway. In the present study, HeyL-KO mice showed no difference in muscle weight relative to control mice at 1 week after tenotomy, when increased myofiber size was already observed ([@bib23]). However, the loss of *Heyl* affected both muscle weight and myofiber size at 9 weeks after SA. Additionally, [@bib14] noted that the absence of MuSCs affected the late stage (8 weeks) of SA-induced muscle hypertrophy. Collectively, the results of the present study indicated that the early stage of muscle hypertrophy does not require MuSCs, but that the addition of new MuSC-derived myonuclei was responsible for long-term increases in myofiber mass.

In summary, our findings reveal an essential mechanism underlying MuSC proliferation during muscle hypertrophy ([Figure 7A](#fig7){ref-type="fig"}). Identification of factors and mechanism that induce MuSC activation/proliferation under HeyL expression could lead to the development of MuSC-based therapeutic strategies for muscle-wasting diseases.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                                            Source or\                                                                              Identifiers                                                                            Additional\
  (species) or resource                                                                                               reference                                                                                                                                                                      information
  -------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------
  Strain, strain background (*Mus musculus*)   Hey1-KO                                                                PMID: [15680351](https://www.ncbi.nlm.nih.gov/pubmed/15680351)                          MGI:3574059                                                                            [@bib25]

  Strain, strain background (*Mus musculus*)   Heyl-KO                                                                PMID: [21989910](https://www.ncbi.nlm.nih.gov/pubmed/21989910)                          MGI:5302514                                                                            [@bib16]

  Strain, strain background (*Mus musculus*)   Pax7^CreERT2/+^                                                        The Jackson Laboratory PMID: [19554048](https://www.ncbi.nlm.nih.gov/pubmed/19554048)   JAX:\# 012476\                                                                         
                                                                                                                                                                                                              RRID:[IMSR_JAX:012476](https://scicrunch.org/resolver/IMSR_JAX:012476)                 

  Strain, strain background (*Mus musculus*)   Rosa26^EYFP^                                                           The Jackson Laboratory PMID: [19554048](https://www.ncbi.nlm.nih.gov/pubmed/19554048)   JAX:\# 006148\                                                                         
                                                                                                                                                                                                              RRID:[IMSR_JAX:006148](https://scicrunch.org/resolver/IMSR_JAX:006148)                 

  Antibody                                     anti-CD31-FITC (rat monoclonal)                                        BD Biosciences                                                                          Cat\# 558738\                                                                          1:400
                                                                                                                                                                                                              RRID:[AB_397097](https://scicrunch.org/resolver/AB_397097)                             

  Antibody                                     anti-CD45-FITC (rat monoclonal)                                        eBioscience                                                                             Cat\# 11-0451-82\                                                                      1:800
                                                                                                                                                                                                              RRID:[AB_465050](https://scicrunch.org/resolver/AB_465050)                             

  Antibody                                     anti-Sca1-PE (rat monoclonal)                                          BD Biosciences                                                                          Cat\# 553336\                                                                          1:400
                                                                                                                                                                                                              RRID:[AB_394792](https://scicrunch.org/resolver/AB_394792)                             

  Antibody                                     anti-Satellite cells (rat monoclonal)                                  [@bib15] ECR 296, 245--255.                                                                                                                                                    1:200

  Antibody                                     anti-Dystrophin (rabbit polyclonal)                                    Abcam                                                                                   Cat\# ab15277, RRID:[AB_301813](https://scicrunch.org/resolver/AB_301813)              1:800

  Antibody                                     anti-eMyHC (mouse monoclonal)                                          DSHB                                                                                    Cat\# F1.652\                                                                          1:2 (Supernatant)
                                                                                                                                                                                                              RRID:[AB_528358](https://scicrunch.org/resolver/AB_528358)                             

  Antibody                                     anti-GFP (YFP) (goat polyclonal)                                       SICGEN                                                                                  Cat\# AB0020-200, RRID:[AB_2333099](https://scicrunch.org/resolver/AB_2333099)         1:1000

  Antibody                                     anti-GFP (YFP) (rabbit polyclonal)                                     MBL                                                                                     Cat\# 598S, RRID:[AB_591816](https://scicrunch.org/resolver/AB_591816)                 1:1000

  Antibody                                     anti-Ki67 (rat monoclonal)                                             Thermo Fisher Scientific                                                                Cat\# 14-5698-82\                                                                      1:200
                                                                                                                                                                                                              RRID:[AB_10854564](https://scicrunch.org/resolver/AB_10854564)                         

  Antibody                                     anti-Laminin a2 (rat monoclonal)                                       Enzo Life Sciences                                                                      Cat\#ALX-804--190 C100, RRID:[AB_2051764](https://scicrunch.org/resolver/AB_2051764)   1:200

  Antibody                                     anti-M-cadherin (rabbit polyclonal)                                    [@bib38]                                                                                                                                                                       1:1000

  Antibody                                     anti-MyoD (rabbit polyclonal)                                          Santa Cruz                                                                              Cat\# sc-760\                                                                          1:200
                                                                                                                                                                                                              RRID:[AB_2148870](https://scicrunch.org/resolver/AB_2148870)                           

  Antibody                                     anti-MyoD (mouse monoclonal)                                           BD Biosciences                                                                          Cat\# 554130\                                                                          1:200
                                                                                                                                                                                                              RRID:[AB_395255](https://scicrunch.org/resolver/AB_395255)                             

  Antibody                                     anti-Pax7 (mouse monoclonal)                                           DSHB                                                                                    Cat\# PAX7\                                                                            1:2 (Supernatant)
                                                                                                                                                                                                              RRID:[AB_528428](https://scicrunch.org/resolver/AB_528428)                             

  Commercial assay or kit                      Click-iT EdU Cell Proliferation Kit for Imaging, Alexa Fluor 647 dye   Thermo Fisher Scientific                                                                \#C10340                                                                               

  Chemical compound, drug                      EdU                                                                    Thermo Fisher Scientific                                                                \#A10044                                                                               

  Chemical compound, drug                      Cardiotoxin                                                            Latoxan                                                                                 Cat\# L8102                                                                            10 µM

  Chemical compound, drug                      Tamoxifen                                                              Sigma-Aldrich                                                                           Cat\# T5648-1G                                                                         

  Others                                       DAPI                                                                   Vector Laboratories                                                                     Cat\# H-1200                                                                           

  Others                                       MOM blocking                                                           Vector Laboratories                                                                     Cat\# BMK-2202                                                                         

  Sequence-based reagent                       5'-TGTGGATCACCTGAAAATGC                                                Eurofins                                                                                N/A                                                                                    qPCR Hey1 (Forward primer)

  Sequence-based reagent                       5'-ACCCCAAACTCCGATAGTCC                                                Eurofins                                                                                N/A                                                                                    qPCR Hey1 (Reverse primer)

  Sequence-based reagent                       5'-CAGCCCTTCGCAGATGCAA                                                 Eurofins                                                                                N/A                                                                                    qPCR Heyl (Forward primer)

  Sequence-based reagent                       5'-CCAATCGTCGCAATTCAGAAAG                                              Eurofins                                                                                N/A                                                                                    qPCR Heyl (Reverse primer)

  Sequence-based reagent                       5'-GCTACTCCTGTTCCTGCTGC                                                Eurofins                                                                                N/A                                                                                    qPCR Col5a1 (Forward primer)

  Sequence-based reagent                       5'-TGAGGGCAAATTGTGAAAATC                                               Eurofins                                                                                N/A                                                                                    qPCR Col5a1 (Reverse primer)

  Sequence-based reagent                       5'-CCGGAGACTGGATCAGCTT                                                 Eurofins                                                                                N/A                                                                                    qPCR Col5a3 (Forward primer)

  Sequence-based reagent                       5'-GCTTCCAGTACGTCCACAGG                                                Eurofins                                                                                N/A                                                                                    qPCR Col5a3 (Reverse primer)

  Sequence-based reagent                       5'-TACTTCGGGAAAGGCACCTA                                                Eurofins                                                                                N/A                                                                                    qPCR Col6a1 (Forward primer)

  Sequence-based reagent                       5'-TCGGTCACCACGATCAAGT                                                 Eurofins                                                                                N/A                                                                                    qPCR Col6a1 (Reverse primer)

  Chemical compound, drug                      Trizol LS reagent                                                      Thermo Fisher Scientific                                                                Cat\# 10296028                                                                         

  Chemical compound, drug                      RNeasy mini kit                                                        QIAGEN                                                                                  Cat\# 74104                                                                            

  Software, algorithm                          Photophop CC                                                           <https://www.adobe.com/products/photoshop.html>                                         RRID:[SCR_014199](https://scicrunch.org/resolver/SCR_014199)                           

  Software, algorithm                          Hybrid Cell count                                                      <https://www.keyence.com/ss/products/microscope/bz-x/products-info/quantify.jsp>                                                                                               

  Software, algorithm                          UMI-tools                                                              <https://github.com/CGATOxford/UMI-tools>                                                                                                                                      v.1.1.0

  Software, algorithm                          HISAT2                                                                 <https://ccb.jhu.edu/software/hisat2/index.shtml>                                                                                                                              v.2.1.0

  Software, algorithm                          featureCounts                                                          <http://subread.sourceforge.net/>                                                                                                                                              v.1.6.4

  Software, algorithm                          DESeq2                                                                 <https://bioconductor.org/packages/release/bioc/html/DESeq2.html>                       DOI: [10.18129/B9.bioc.DESeq2](http://doi.org/10.18129/B9.bioc.DESeq2)                 v.1.22.2
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

C57BL/6J mice were purchased from Charles River Laboratories (Yokohama, Kanagawa, Japan). *Hey1^−/−^* mice and *Heyl^−/−^* mice were described previously ([@bib16]; [@bib25]). *Pax7^CreERT2+^* mice (stock No: 012476) were obtained from Jackson Laboratories (Bar Harbor, ME, USA; Farmington, CT, USA; or Sacramento, CA, USA). Relocation of *Rosa26^EYFP/+^* mice (stock No: 006148) from the National Center of Neurology and Psychiatry to Osaka University was approved by Jackson Laboratories. *Pax7^CreERT2+^::Rosa26^EYFP/+^* mice were injected intraperitoneally twice (24 hr apart) with 200 μl to 300 μl tamoxifen (20 mg/ml; \#T5648; Sigma-Aldrich, St. Louis, MO, USA) dissolved in sunflower seed oil (\#S5007; Sigma-Aldrich) and 5% ethanol, and the mice were maintained in a controlled environment (temperature, 24 ± 2°C; humidity, 50 ± 10%) under a 12/12 hr light/dark cycle. The mice received sterilized standard chow (DC-8; Nihon Clea, Tokyo, Japan) and water *ad libitum*. All procedures used for the experimental animals were approved by the Experimental Animal Care and Use Committee of Osaka University (approval number: 25-9-3, 30--15).

Muscle-overload model {#s4-2}
---------------------

Mice were anesthetized with isoflurane. Functional overloading of plantaris muscle was induced as described in a previous report ([@bib23]). Briefly, a midline incision was made in the skin on the hindlimbs, and the distal tendons of both gastrocnemius and soleus muscles were transected (tenotomy). In the experiments shown in [Figure 6](#fig6){ref-type="fig"}, the overloading of plantaris muscle was induced by excising the distal half of both the gastrocnemius and the soleus (i.e., SA was performed). The incision was closed using a 7--0 silk suture (Matsuda Ika Kogyo Co., Ltd., Tokyo, Japan). For the sham-operated group, similar incisions were made in the skin, but the tendons were not transected. Muscle weights were normalized against body weights.

Muscle-injury model {#s4-3}
-------------------

Muscle regeneration was induced by injecting 10 μM CTX (Latoxan, Valence, France) in phosphate-buffered saline (PBS) into the tibialis anterior muscle (50 μl).

Muscle fixation and histologic analysis {#s4-4}
---------------------------------------

Isolated plantaris or tibialis anterior muscles were frozen in liquid-nitrogen-cooled isopentane (Wako Pure Chemicals Industries, Osaka, Japan) for 1 min and then placed on dry ice for 1 hr to vaporize the isopentane. Transverse cryosections (10 μm) were stained with hematoxylin and eosin (H and E).

For immunohistochemical analyses, transverse cryosections (6 μm) were fixed with 4% paraformaldehyde (PFA) for 10 min. For embryonic myosin heavy chain (eMyHC) staining, sections were fixed with cooled acetone for 10 min at −20°C. Detailed information on antibodies used in this study is provided in Key Resource Table. For mouse anti-Pax7 and -eMyHC staining, a M.O.M. kit (Vector Laboratories, Burlingame, VT, USA) was used to block endogenous mouse IgG before reacting with the primary antibodies. The signals were recorded photographically using a BZ-X700 fluorescence microscope (Keyence, Osaka, Japan).

Single-myofiber isolation, culture, and staining {#s4-5}
------------------------------------------------

Single myofibers were isolated from plantaris muscles according to a previously described protocol ([@bib41]). The isolated myofibers were immediately fixed in 4% PFA or cultured in high-glucose Dulbecco's modified Eagle medium containing 10% fetal calf serum. Immunostaining was performed using previously described protocols ([@bib8]; [@bib45]), and the stained myofibers were recorded using a BZ-X700 fluorescence microscope (Keyence).

In vivo EdU labeling and detection {#s4-6}
----------------------------------

EdU (\#A10044; Thermo Fisher Scientific, Waltham, MA, USA) was dissolved in PBS at 0.5 mg/ml and injected intraperitoneally into mice at 0.1 mg per 20 g body weight (5 mg/kg) daily until the day before sacrifice. EdU labeling was detected using the protocol supplied by the manufacturer (\#C10340; Thermo Fisher Scientific).

Isolation of skeletal muscle-derived mononuclear cells {#s4-7}
------------------------------------------------------

Sham or overloaded plantaris muscles or uninjured/injured limb muscles were digested using 0.2% collagenase type II (Worthington Biochemical, Lakewood, NJ, USA). Mononuclear cells derived from skeletal muscle were stained with FITC-conjugated anti-CD31 and anti-CD45, PE-conjugated anti-Sca-1, and biotinylated-SM/C-2.6 antibodies ([@bib15]). Subsequently, the cells were incubated with streptavidin-labeled allophycocyanin (BD Biosciences, San Jose, CA, USA) on ice for 30 min and resuspended in PBS containing 2% fetal bovine serum and 2 mg/ml propidium iodide. Cell sorting was performed using a FACS Aria II flow cytometer (BD Immunocytometry Systems, San Jose, CA, USA). Muscle stem cells from *Pax7^CreERT2+^::Rosa^YFP^* mice were sorted by yellow fluorescent protein fluorescence (YFP) for RNA-seq analyses.

RNA isolation and qRT-PCR analysis {#s4-8}
----------------------------------

Total RNA was extracted from sorted cells by using Trizol LS reagent (Thermo Fisher Scientific) and a QIAGEN RNeasy mini kit according to the manufacturer instructions (QIAGEN, Hilden, Germany) and then reverse-transcribed into cDNA using a QuantiTect reverse transcription kit (QIAGEN). Specific forward and reverse primers used for optimal amplification during real-time PCR of reverse-transcribed cDNAs are listed in Key Resource Table.

CEL-Seq2 and data analysis {#s4-9}
--------------------------

Cells were sorted into tubes containing lysis buffer at 100 cells/tube using a cell sorter (Aria II). Libraries were constructed according to a previously described protocol ([@bib20]) and sequenced using an Illumina HiSeq 1500 system (Illumina, San Diego, CA, USA). The barcodes and unique-molecular-identifiers in the reads were extracted using UMI-tools (v.1.0.0) ([@bib47]) with the following command: \'`umi_tools extract -I r1.fastq --read2-in = r2.fastq --bc-pattern=NNNNNNCCCCCC --read2-stdout`\'. The reads were mapped to the reference genome (GRCm38) using the alignment software HISAT2 (v.2.1.0) ([@bib24]). Read counts per gene were determined using featureCounts (v.1.6.4) ([@bib30]) and UMI-tools using the following command: \'`umi_tools count --method=directional per-gene --per-cell --gene-tag=XT'`. Duplicates among unique molecular identifiers were discarded. Differentially expressed genes (adjusted p\<0.1) were extracted using the R library program DESeq2 (v.1.22.2) ([@bib31]). Data were deposited with the accession number GSE135903. Gene-expression data for myogenic cells at 2 days after CTX injection are available under accession number GSE56903 ([@bib37]).

Statistics {#s4-10}
----------

Values are expressed as the mean ± standard deviation Statistical significance was assessed using the F test, followed by Student's *t* test. When p\<0.05 for the F test, Welch's *t* test was used. For comparisons more than two groups, we used non-repeated measures analysis of variance (ANOVA), followed by the Tukey--Kramer test. When p≥0.05 for the ANOVA results, a Bonferroni test (vs. control) was used ([Figure 5D](#fig5){ref-type="fig"}). A p\<0.05 or p\<0.01 was considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Different requirement of *HeyL* in proliferating muscle stem cells in overloaded versus regenerating muscle\" consideration by *eLife*. Your article has been reviewed by three peer reviewers, including a guest Reviewing Editor, and the evaluation has been overseen by Didier Stainier as Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting manuscript that shows that the mode of muscle stem cell activation differs between cardiotoxin-mediated injury and overloading-induced hypertrophy. It remains an open question how much from injury-model can be applied to more physiological settings. Unexpectedly, the authors find different features in the overloading model -- specifically, the stem cells are activated / proliferate / fuse while *MyoD* is weakly induced. Mechanistically, one of the Notch pathway targets, *HeyL*, is sustained in overload model, which in turn might suppress *MyoD*. Loss of *HeyL* decreases stem cell activation and fusion in the overload model, and the authors interpret that accumulation of *MyoD* forces the stem cells to differentiate. Overall, this is a potentially interesting paper trying to address an important question. However, there are some unclear points and potentially alternative explanations about what the authors are observing. Additional experiments are needed in order to substantiate the conclusions.

Major concern:

The interpretation that *HeyL* KO mouse fails to induce *MyoD* is ambiguous. In CTX injury model, both *HeyL*/Hey1 goes down leading to an stronger *MyoD* induction. An alternative explanation is that all the pathways are just less strongly activated in the overload model compared to injury -- not necessarily that there is a completely different mechanism of activation. Indeed, the extent of stem cell number increase is small in overload compared to injury (Figure 1D). This could be the reason why *MyoD* induction is also weaker. Further, Hey1 might be just a less efficient target of Rbpj, and that could be the reason why only Hey1 is down-regulated while *HeyL* is sustained. In this point of view, it would be much more convincing if the authors could perform unbiased transcriptome analysis of the stem cells in injury versus overload, and show that there are actually a group of genes that goes up in overload model.

Overall, this manuscript is well written, interesting and timely and might help find a new mode of activation of satellite cells in the absence of aggressive muscle damage such as cardiotoxin-induced injury. We have the following suggestions to improve the manuscript.

Essential revisions:

1\) The authors mentioned that *MyoD*- MuSCs undergo cell proliferation during muscle overloading within the intact myofibers. However, this data is still missing. Please show *MyoD*, EdU and laminin staining, and possibly in combination with Pax7 in overloaded muscle sections. Especially, the authors should analyze time course-dependent kinetics of MuSC activation, entering cell cycle and exiting cell cycle, and fusion to intact myofibers during muscle overloading. This data will confirm that MuSC located underneath the basal lamina can enter cell cycle and contribute to myonuclei during overloading. Similar immunodetection should be performed for overloaded muscle sections in *HeyL* KO mice.

2\) \"importantly, at 4 days after tenotomy, the percentage of Pax7+Ki67+ cells among Pax7+ cells (\~70%) was higher than that of Pax7+*MyoD*+ cells (\~35%), which suggested that most of these MuSCs proliferated in the absence of *MyoD* expression.\" This statement is a gross oversimplification, since it is unclear whether the majority of Pax7+Ki67+ cells are proliferating. Maybe only half are cycling?

3\) Subsection "Proliferation of MuSCs during muscle hypertrophy", last paragraph: These results suggested that MuSC proliferation does not occur in a restricted area of the overloaded myofibers and that almost all myofibers respond to the overload, which awakens MuSCs from quiescence. Again the authors use Ki67 expression as synonym with proliferation- which it is not. It is an indication that cells are not quiescent.

4\) In Figure 3, *Hes1* expression should be included since MuSC can express *Hes1* according to the publication (Lahmann et al., 2019).

5\) Changes in gene expression in the overload model. Only *Hey/HeyL* and a couple of collagen genes are tested. Please provide a rational for selecting these collagens. The authors should analyze a broader set of Notch target genes and other myogenic markers. Best would be to provide RNAseq data, or at least a broad set of Notch target genes including more members of the Hes/Hey family, Notch ligands and receptors, *MyoD* and other myogenic transcription factors (*Myf5* etc.). Please provide SEM / error bars for experiment Figure 3B and C.

6\) The finding suggests that MuSCs proliferate under activation of canonical Notch signaling in the overload mouse model and that MuSCs lose Hey1 expression despite Notch signaling being active. This is an over-interpretation of the scarce data provided. The fact that one gene (*HeyL*) is upregulated provides no evidence that Notch signaling is active. The authors could equally argue that Notch signaling is absent since Hey1 is downregulated.

7\) Figure 4: The effects of the *HeyL* mutations on Ki67 and *MyoD* expression are mild; the ratio of *MyoD*+/*MyoD*- cells is larger but extremely variable; it would be nice if n could be increased in this experiment.

8\) Subsection "Supply of new myonuclei is diminished in *HeyL*-KO-mouse overloaded muscle": Approximately 20 or 60 myonuclei were labeled per cross-section from control/Hey1-KO mice at 4 or 7 days after surgery. The quantification of this is unclear since the muscle diameter might be highly variable depending on the section: please quantify not per cross-section but per myofiber or per 100 myofiber nuclei.

9\) Figure 5B -- In the *HeyL* KO image, there are a lot of EdU positive nuclei that are not assigned as myonuclei. In contrast, in control or Hey1 KO, all EdU nuclei are assigned as myonuclei. What are the non-myonuclei/EdU labeled nuclei in the *HeyL* KO? Are they Pax7 positive?

10.7554/eLife.48284.031

Author response

> Major concern:
>
> The interpretation that HeyL KO mouse fails to induce MyoD is ambiguous. In CTX injury model, both HeyL/Hey1 goes down leading to an stronger MyoD induction. An alternative explanation is that all the pathways are just less strongly activated in the overload model compared to injury -- not necessarily that there is a completely different mechanism of activation. Indeed, the extent of stem cell number increase is small in overload compared to injury (Figure 1D). This could be the reason why MyoD induction is also weaker. Further, Hey1 might be just a less efficient target of Rbpj, and that could be the reason why only Hey1 is down-regulated while HeyL is sustained. In this point of view, it would be much more convincing if the authors could perform unbiased transcriptome analysis of the stem cells in injury versus overload, and show that there are actually a group of genes that goes up in overload model.

We thank the reviewers for this careful reading of our manuscript. In myogenic cells, we and other groups previously showed *HeyL* as a critical and direct target of Notch signaling. In the present study, our data indicated a modest increase in the number of satellite cells due to myogenic differentiation (fusion with myofibers), with proliferation simultaneously observed in overloaded muscle. *HeyL* KO failed to suppress *MyoD* expression in overloaded and resulted in no associated phenotype in regenerating muscles, indicating that the sustained expression of *HeyL* is a feature of and important to overloaded MuSCs.

According to the reviewers' suggestion, we added the results of transcriptome analyses of overloaded MuSCs to revised Figure 3.

> Overall, this manuscript is well written, interesting and timely and might help find a new mode of activation of satellite cells in the absence of aggressive muscle damage such as cardiotoxin-induced injury. We have the following suggestions to improve the manuscript.

We are thankful for the recognition of the value of our work. We are confident that the findings will promote an in-depth understanding of MuSC behavior in overloaded muscle.

> Essential revisions:
>
> 1\) The authors mentioned that MyoD- MuSCs undergo cell proliferation during muscle overloading within the intact myofibers. However, this data is still missing. Please show MyoD, EdU and laminin staining, and possibly in combination with Pax7 in overloaded muscle sections. Especially, the authors should analyze time course-dependent kinetics of MuSC activation, entering cell cycle and exiting cell cycle, and fusion to intact myofibers during muscle overloading. This data will confirm that MuSC located underneath the basal lamina can enter cell cycle and contribute to myonuclei during overloading. Similar immunodetection should be performed for overloaded muscle sections in HeyL KO mice.

We appreciate the reviewers' constructive feedback. Since *MyoD* staining in sections is sometimes difficult to judge, we mainly analyzed MuSCs with single myofiber technique. In revised Figure 3, we added results indicating proliferating Pax7^+^ cells beneath the basal lamina. To describe the kinetics of MuSC behavior, we added the following information obtained during muscle overload:

During activation (day 2), \~10% of MuSCs were Ki67^+^ (Figure 1E), and EdU^+^Pax7^+^ cells were not detected (Figure 7---figure supplement 1B), indicating that MuSCs were initially activated at day 2 after tenotomy.

During MuSC proliferation (days 4--7), \~50% to 70% and a half of MuSC were Ki67^+^ (Figure 1E) and EdU^+^, respectively (Figure 7---figure supplement 1B), indicating that MuSCs proliferated between 4 and 7 days after tenotomy.

Upon exit of cell cycle/fusion (days 4--14), EdU^+^ myonuclei were detected at 4 days after tenotomy, and this number gradually increased until 14 days after tenotomy (Figure 5C and Figure 7---figure supplement 1C). These results indicated that MuSCs exited from the cell cycle and fused with myofiber over a long period of time. Results from *HeyL*-KO mice are shown in Figure 5C.

Therefore, compared to regenerating muscle, vigorous proliferation and differentiation occurred simultaneously in overloading muscle. This result explains the attenuated number of MuSCs in overloaded muscle based on the decreased accumulation of proliferating MuSCs. Furthermore RNA-seq data indicated simultaneous expression of cell cycle-related genes and *myogenin*.

At 14 days after tenotomy, we rarely detected Ki67^+^ MuSCs (Figure 1E). Additionally, the number of MuSCs was similar to that in sham muscle (Figure 1D), indicating that these MuSCs returned to a quiescent state at 14 days after tenotomy.

Moreover, all Pax7^+^EdU^+^ cells were located beneath the basal lamina, including in *HeyL*-KO mice. The frequency of Ki67^+^ cells in *HeyL*-KO mice was similar to that in control mice. On the other hand, the number of MuSCs was reduced in *HeyL*-KO mice (Figure 4E), indicating that the reduced number of new myonuclei resulted from impaired MuSC proliferation but not activation.

The following was added to the revised manuscript:

"Based on our results, the kinetics of MuSC behavior in overloaded muscle also differ from those in regenerating muscles (Figure 7A; Figure 7---figure supplement 1A). ---figure supplement\[...\] RNA-seq data supported this model based on elevated expression of both cell cycle-related genes and *myogenin* in overloaded MuSCs."

> 2\) \"importantly, at 4 days after tenotomy, the percentage of Pax7+Ki67+ cells among Pax7+ cells (\~70%) was higher than that of Pax7+MyoD+ cells (\~35%), which suggested that most of these MuSCs proliferated in the absence of MyoD expression.\" This statement is a gross oversimplification, since it is unclear whether the majority of Pax7+Ki67+ cells are proliferating. Maybe only half are cycling?

We thank the reviewers for this comment. The text was changed as follows:

"...suggesting that at least \>50% of these MuSCs proliferated in the absence of *MyoD* expression (Figure 1E, F)."

> 3\) Subsection "Proliferation of MuSCs during muscle hypertrophy", last paragraph: These results suggested that MuSC proliferation does not occur in a restricted area of the overloaded myofibers and that almost all myofibers respond to the overload, which awakens MuSCs from quiescence. Again the authors use Ki67 expression as synonym with proliferation- which it is not. It is an indication that cells are not quiescent.

We thank the reviewer for this important comment. We agree that Ki67 expression does not independently indicate cell proliferation. We changed the text as follows:

"These results suggested that escape of MuSCs from quiescent state did not occur in a restricted area of the overloaded myofibers, and that almost all myofibers responded to the overload."

> 4\) In Figure 3, Hes1 expression should be included since MuSC can express Hes1 according to the publication (Lahmann et al., 2019).

As previously noted, we performed RNA-seq analyses, with the results showing *Hes1* expression indicated in revised Figure 3. The importance of *Hes1* and the *Hes1*--*HeyL* heterodimer were mentioned in the revised manuscript.

"*Hey1, HeyL*, and *Hes1* are crucial primary targets of canonical Notch signaling in MuSCs (Fukada et al., 2011; Lahmann et al., 2019) and function to suppress myogenic differentiation as *Hey*--*Hes1* heterodimer complexes (Noguchi et al., 2019)."

> 5\) Changes in gene expression in the overload model. Only Hey/HeyL and a couple of collagen genes are tested. Please provide a rational for selecting these collagens. The authors should analyze a broader set of Notch target genes and other myogenic markers. Best would be to provide RNAseq data, or at least a broad set of Notch target genes including more members of the Hes/Hey family, Notch ligands and receptors, MyoD and other myogenic transcription factors (Myf5 etc.). Please provide SEM / error bars for experiment Figure 3B and C.

According to the reviewers' comment, we performed RNA-seq analyses and obtained similar results as those obtained from qRT-PCR. The sustained expression of *HeyL* in overloaded MuSCs represents the biggest difference in gene-expression pattern from that for regenerating MuSCs. The expression of Notch target genes and myogenic genes have also been provided in revised Figure 3. These results suggested active Notch signaling in overloaded MuSCs. Moreover, elevated *myogenin* expression suggested the existence of differentiated cells at 4 days after tenotomy (see our response to comment 1). Compared to regenerating MuSCs, the sustained expression of *Myf5* was a new finding.

We could obtain only 1000 MuSCs per one sham plantaris muscle. For qRT-PCR analyses, we used 17 heads to obtain sufficient MuSCs from plantaris muscles. Therefore, there was a substantial limitation of those analyses. We repeated the qRT-PCR analysis using the same samples and obtained same results. Therefore, our conclusion was based on qRT-PCR results.

> 6\) The finding suggests that MuSCs proliferate under activation of canonical Notch signaling in the overload mouse model and that MuSCs lose Hey1 expression despite Notch signaling being active. This is an over-interpretation of the scarce data provided. The fact that one gene (HeyL) is upregulated provides no evidence that Notch signaling is active. The authors could equally argue that Notch signaling is absent since Hey1 is downregulated.

We added the following information to the revised manuscript:

"Although RNA-seq data strongly suggested active Notch signaling in the overloaded MuSCs, we cannot exclude the possibility that Notch signaling is inactive in proliferating MuSCs, and that a Notch-independent mechanism induces *Heyl* expression."

> 7\) Figure 4: The effects of the HeyL mutations on Ki67 and MyoD expression are mild; the ratio of MyoD+/MyoD- cells is larger but extremely variable; it would be nice if n could be increased in this experiment.

We added this information to the revised manuscript accordingly \[control (*n* = 1) and *HeyL*-KO (*n* = 2)\].

> 8\) Subsection "Supply of new myonuclei is diminished in HeyL-KO-mouse overloaded muscle": Approximately 20 or 60 myonuclei were labeled per cross-section from control/Hey1-KO mice at 4 or 7 days after surgery. The quantification of this is unclear since the muscle diameter might be highly variable depending on the section: please quantify not per cross-section but per myofiber or per 100 myofiber nuclei.

According to the reviewers' suggestion, we added data indicating EdU^+^ myonuclei per 100 myofibers (Figure 5---figure supplement 1A). These data indicated significant decreases in the number of EdU^+^ cells per 100 myofibers in *HeyL*-KO mice.

> 9\) Figure 5B -- In the HeyL KO image, there are a lot of EdU positive nuclei that are not assigned as myonuclei. In contrast, in control or Hey1 KO, all EdU nuclei are assigned as myonuclei. What are the non-myonuclei/EdU labeled nuclei in the HeyL KO? Are they Pax7 positive?

We apologize for the confusion regarding the *HeyL* results. EdU^+^ cells outside of the dystrophin-staining area represent satellite cells, mesenchymal progenitors, and hematopoietic cells. To avoid confusing readers on this point, the original images were replaced with new ones. Additionally, we did not observe clear Pax7^+^EdU^+^ cells outside of the basal lamina. Now, we have investigated the roles of interstitial cells during muscle hypertrophy and will answer the role of interstitial EdU^+^ cells in future study.
